End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
20.07 CNY | +2.14% | +0.40% | -9.31% |
May. 16 | Hualan Biological Engineering's Blood Centers Get License to Operate | MT |
Apr. 25 | Hualan Biological Engineering Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.31% | 4.98B | C- | ||
-3.05% | 90.45B | A- | ||
+3.95% | 41.45B | A- | ||
-10.51% | 33.57B | B- | ||
+60.58% | 25.73B | A | ||
-20.09% | 14.73B | C | ||
-8.92% | 12.82B | B- | ||
-11.46% | 11.7B | D+ | ||
-43.05% | 11.44B | B | ||
+5.17% | 8.79B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002007 Stock
- Ratings Hualan Biological Engineering Inc.